Apixaban versus Warfarin in Patients with Atrial Fibrillation

阿哌沙班 医学 心房颤动 华法林 阿司匹林 冲程(发动机) 内科学 心脏病学 拜瑞妥 人口 机械工程 环境卫生 工程类
作者
Christopher B. Granger,John H. Alexander,John J.V. McMurray,Renato D. Lópes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al‐Khalidi,Jack Ansell,Dan Atar,Álvaro Avezum,M. Cecilia Bahit,Rafael Díaz,J. Donald Easton,Justin A. Ezekowitz,Greg Flaker,David García,Margarida Geraldes,Bernard J. Gersh,Golitsyn Sp,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Janský,Basil S. Lewis,José López‐Sendón,Prem Pais,Alexander Parkhomenko,Freek W.A. Verheugt,Jun Zhu,Lars Wallentin
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:365 (11): 981-992 被引量:8312
标识
DOI:10.1056/nejmoa1107039
摘要

Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause.The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P=0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P=0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P=0.42).In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
3秒前
莓莓发布了新的文献求助10
4秒前
FG完成签到,获得积分10
4秒前
爆米花的应助被简单山水采纳,获得10
4秒前
上官若男的应助被雾潋采纳,获得10
5秒前
Kiss完成签到,获得积分10
7秒前
cdercder的应助被fzt采纳,获得10
7秒前
7秒前
GBY完成签到,获得积分10
8秒前
LIUJIAWEI发布了新的文献求助10
9秒前
Maestro_S的应助被一呆采纳,获得10
9秒前
GBY发布了新的文献求助10
10秒前
BINBIN完成签到,获得积分10
12秒前
顺利的盼曼完成签到 ,获得积分10
13秒前
我的djwhjja发布了新的文献求助10
13秒前
1234完成签到,获得积分10
15秒前
creach完成签到,获得积分10
15秒前
科研通AI6.3的应助被WZJ采纳,获得10
16秒前
悦耳凤灵完成签到,获得积分10
17秒前
Jasper的应助被李飞龙采纳,获得10
17秒前
领导范儿的应助被xiaobai采纳,获得10
20秒前
Jun的应助被GBY采纳,获得10
20秒前
20秒前
21秒前
我的djwhjja完成签到,获得积分10
21秒前
21秒前
光亮发卡发布了新的文献求助10
21秒前
李健的小迷弟的应助被yosh采纳,获得10
21秒前
creach发布了新的文献求助10
22秒前
pp完成签到,获得积分10
22秒前
22秒前
不爱喝酒的应助被interest-li采纳,获得10
23秒前
852的应助被wwwwwl采纳,获得30
23秒前
Owen的应助被interest-li采纳,获得10
23秒前
23秒前
Maestro_S的应助被interest-li采纳,获得10
24秒前
LLL完成签到,获得积分10
24秒前
12121发布了新的文献求助10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568